ADRIATIC
ADRIATIC brought the first improvement in curative-intent small-cell lung cancer treatment in 30 years: a year or two of immunotherapy after chemoradiation lengthens life.
Median OS 55.9 vs 33.4 months (HR 0.73); PFS 16.6 vs 9.2 months (HR 0.76). FDA approval 4 December 2024; the PACIFIC template applied to SCLC. Benefit held regardless of prophylactic cranial irradiation. Durvalumab + tremelimumab arm results were reported separately.
- Median 55.9 vs 33.4 months with Durvalumab compared with Placebo; about 22.5 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 27 percent lower chance of the event at any given time (hazard ratio 0.73, likely range 0.57 to 0.93).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- Median 16.6 vs 9.2 months with Durvalumab compared with Placebo; about 7.4 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 24 percent lower chance of the event at any given time (hazard ratio 0.76, likely range 0.61 to 0.95).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Limited-stage SCLC without progression after concurrent chemoradiotherapy: durvalumab consolidation (up to 2 years) vs placebo. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
730 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Durvalumab | 264 | 55.9 months | 0.73 (0.57–0.93) | 0.0104 | link |
| Placebo | 266 | 33.4 months | ||||
| Progression-free survivalprimary | Durvalumab | — | 16.6 months | 0.76 (0.61–0.95) | — | — |
| Placebo | — | 9.2 months |
Pages like this
not linked directly; found by shared links- TrialCONVERT
Shares Limited-stage vs extensive-stage (SCLC), Small-cell lung cancer, IMRT / IGRT (modern external beam).
- TermLimited-stage vs extensive-stage (small-cell lung cancer)
Shares Prophylactic cranial irradiation vs MRI surveillance, Durvalumab, Small-cell lung cancer.
- IdeaMRI surveillance replaces prophylactic cranial irradiation in SCLC
Shares Prophylactic cranial irradiation vs MRI surveillance, Small-cell lung cancer.
- TermProphylactic cranial irradiation (PCI)
Shares Prophylactic cranial irradiation vs MRI surveillance, Small-cell lung cancer.
- TrialCASPIAN
Shares Durvalumab, Small-cell lung cancer.
- TrialDeLLphi-305
Shares Durvalumab, Small-cell lung cancer.
- TrialPACIFIC
- Key paperADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer
Shares Durvalumab, Small-cell lung cancer, IMRT / IGRT (modern external beam).